New psychoactive substances (NPS) are commonly referred to as 'research chemicals' , 'designer drugs' or 'legal highs'. One NPS class is represented by dissociative anesthetics, which include analogues of the arylcyclohexylamine phencyclidine (PCP), ketamine and diphenidine. A recent addition to the NPS market was 4-[1-(3-methoxyphenyl)cyclohexyl] morpholine (3-MeO-PCMo), a morpholine analogue of 3-MeO-PCP. Although suspected to have dissociative effects in users, information about its pharmacological profile is not available. From clinical and forensic perspectives, detailed analytical data are needed for identification, especially when facing the presence of positional isomers, as these are frequently unavailable commercially. This study presents the analytical and pharmacological characterization of 3-MeO-PCMo along with five additional analogues, namely the 2-and 4-MeO-PCMo isomers, 3,4-methylenedioxy-PCMo (3,4-MD-PCMo), 3-Me-PCMo and PCMo. All six arylcyclohexylmorpholines were synthesized and characterized using chromatographic, mass spectrometric and spectroscopic techniques. The three positional isomers could be differentiated and the identity of 3-MeO-PCMo obtained from an internet vendor was verified. All six compounds were also evaluated for affinity at 46 central nervous system receptors including the N-methyl-D-aspartate receptor (NMDAR), an important target for dissociative anesthetics such as PCP and ketamine. In vitro binding studies using (+)-[3- temperatures were set at 310, 80 and 220°C, respectively. The carrier gas was helium at a flow rate of 1 mL/min using the EFC constant flow 
More recently, 1,2-diarylethylamines such as diphenidine and its 2-methoxy analogue 2-MXP have also appeared. 3, 4 Substances that target the NMDAR are of interest for the development of treatment options for conditions such as depression, neuropathic pain and a variety of neurodegenerative disorders and dementias. [5] [6] [7] [8] [9] At the same time, a number of these substances are used recreationally, outside of a medical setting, and include compounds that have not undergone any substantial pharmacological and toxicological evaluations. A systematic methodology is needed in order to address the chemical, pharmacodynamic and pharmacokinetic properties of these substances, 3, 4, 10, 11 thus facilitating drug development efforts, and identification of toxicity profiles as well as adverse events associated with recreational drug use. [12] [13] [14] The earliest reported synthesis of 4-(1-phenylcyclohexyl)morpholine (PCMo) was found in a patent submitted in 1954 15 and predates that of PCP 16 . However, its pharmacology, or dissociative profile, induced in adult female rats. 17 In the tail immersion test, analgesic effects were found to be more pronounced compared to PCP and PCMo. 17 PCMo was also demonstrated to display lower potencies compared to PCP in a range of in vitro and in vivo assays targeting a number of different receptors. [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] Morpholine analogues investigated in the present study. The numbering scheme employed for 13 C NMR assignments is shown for the isomers substituted with methoxy groups temperatures were set at 310, 80 and 220°C, respectively. The carrier gas was helium at a flow rate of 1 mL/min using the EFC constant flow 
| Infrared spectroscopy
Infrared (IR) spectra were obtained with a PerkinElmer Spectrum BX FTIR model (Llantrisant, UK) using a Pike MIRacle ATR system. Data were acquired with the Spectrum v5.01 software (scan range 400-4000 cm −1 , resolution 4 cm −1 , 16 scans). Spectral data can be found in the supporting information.
| Microwave synthesizer
Conversions from primary amine intermediate to morpholine-ring products were performed using a CEM Discover SP microwave synthesizer (CEM Corporation, Matthews, NC, USA). Reactions were carried out in 35 mL microwave vessels from CEM. Conditions for the reactions are detailed below.
| Synthesis procedures
The syntheses of the primary amine intermediates were performed using a modified Geneste route ( Figure 2 ) as described previously. 5, 10, 32 Reactions starting from the primary amine intermediate to yield the morpholine ring products were carried out in a CEM Discover SP microwave synthesizer. The primary amine (PCA) intermediates were available from previous studies. ).
An alternative route for the synthesis of PCMo was also employed and is provided in the supporting information. Experiments were performed in duplicate and repeated three times.
| NMDAR binding studies

| Non-NMDAR binding studies
Competitive binding studies of PCMo and analogues at 45 additional CNS receptors were performed through the National Institute of Mental Health Psychoactive Drug Screening Program (NIMH PDSP).
Briefly, target compounds were dissolved in dimethyl sulfoxide and subjected to primary screening at 10,000 nM concentrations.
Compounds exhibiting >50% inhibition underwent secondary assay at varying concentrations to determine K i values. Additional experimental details are available in the NIMH PDSP assay protocol book. 41 
| RESULTS AND DISCUSSION
The six morpholine analogues investigated in this study ( Figure 1B) were synthesized using the modified Geneste route as reported previously for the preparation of PCP and PCPy analogues. 5, 10, 32 The conversion from the primary amine (PCA) to the morpholine ring was performed using an S N 2 cyclization reaction between the substituted PCA material and bis(2-bromoethylether) ( Figure 2 ) and gave~45% UHPLC electrospray quadrupole time-of-flight tandem mass spectra for all six PCMo analogues are shown in Figure 4 , which illustrated that product ion formations were also comparable to a number of PCP/PCPy 10 and N-alkylarylcyclohexylamine analogues. 5 Examples observed in Figure 4 include a neutral loss of morpholine, formation of the respective tropylium ion or detection of protonated morpholine. Implementation of the HPLC-DAD procedure showed only partial separation of the three positional isomers due to co-elution of 3-MeO-and 4-MeO-PCMo ( Figure 5 ). However, the UV spectra Detailed NMR analyses of PCMo have been reported previously and were consistent with the results presented in this study (Tables 1   and 2) . 44, 45 PCMo HCl was also characterized using 13 C NMR and the recorded spectrum was in agreement with the literature. 36 In general, the chemical shift behavior of the series was consistent with those observed previously with related arylcyclohexylamines and a detailed discussion can be found elsewhere. and β-positions on the other hand were equivalent in all three positional isomers. This effect was observed with the corresponding PCP HCl salt series 30 although it was not consistently observed with the N-alkyl secondary anisylcyclohexylamines. to PCP in a number of experimental models. 46, 47 The affinity rank order determined in this study was comparable to that of their PCP counterparts with 3-MeO > H > 2-MeO > 4-MeO. 30 Interestingly, the same affinity order was seen with a series of diphenidine analogues, 4 although it was not observed with the methoxylated PCPy series (3-MeO > 4-MeO > 2-MeO).
30
A heatmap containing the results of the binding experiments on the 46 assessed CNS receptors is presented in Figure 7 . Besides NMDAR, all compounds had moderate affinity for the sigma-2 receptor, which is commonly seen with this class of compounds. 4, 30, 48 3,4-MD-PCMo was the most selective compound and this selectivity was consistent with other 3,4-MD substituted arylcyclohexylamines. 30 Likewise, 3,4-MD-PCMo and PCMo had moderate NMDAR affinity values comparable to ketamine and memantine. 4, 49, 50 PCMo was shown to be less potent and toxic than PCP, 24 which may be explained by the moderate NMDAR affinity. 30, 49, 50 Arylcyclohexylamines have displayed variable affinities at the monoamine reuptake transporters for serotonin, norepinephrine and dopamine (SERT, NET and DAT, respectively). 30, 51 Interestingly, the morpholine ring abolished NET activity for all compounds relative to their piperidine counterparts. 30 3-Me-PCMo was the only compound with affinity for both SERT and DAT. The 2-MeO and 3-MeO analogues displayed selectivity towards SERT over DAT, whereas 4-MeO-PCMo had appreciable affinity for DAT.
Larger 1,4-diaminocyclohexane derivatives containing the PCMo moiety displayed in vitro μ-opioid receptor activity in previous cellbased assays. 52 However, the binding experiments in this study revealed no affinity for the δ-, κ-or μ-opioid receptors, which indicate that the anti-nociceptive properties may have been the result of NMDAR antagonism. [53] [54] [55] [56] Previous pharmacological experiments with PCMo, 2-MeO-PCMo, 4-Me-PCMo and 2-Me-4-HO-PCMo found analgesic activity in rats 17 which further suggests analgesic effects being mediated independently from opioid receptor affinity. 
